EAM Global Investors’s AnaptysBio ANAB Stock Holding History

EAM Global Investors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-58,683	Closed	-$2.04M	–	201
2021 Q4	$2.04M	Buy	+58,683	New	+$1.86M	0.36%	154
2018 Q2	–	Sell	-19,179	Closed	-$2M	–	152
2018 Q1	$2M	Sell	19,179 -2,555	-12%	-$288K	1.03%	4
2017 Q4	$2.19M	Buy	+21,734	New	+$1.6M	1.12%	5

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM Global Investors's ANAB Position: Q1 2022 in Review

EAM Global Investors sold out of AnaptysBio (ANAB) in Q1 2022, closing a stake of 58,683 shares — an estimated $2.04M sold.

EAM Global Investors first reported a position in ANAB in Q4 2017 and held it in 3 quarters. The position peaked at $2.19M in Q4 2017. 131 funds tracked by Wall St. Rank hold ANAB as of Q1 2022.

EAM Global Investors reported no remaining AnaptysBio position as of Q1 2022 after selling out during the quarter.
EAM Global Investors sold 58,683 AnaptysBio shares in Q1 2022, an estimated $2.04M.
EAM Global Investors first reported a position in AnaptysBio in Q4 2017 and held it in 3 quarters.
EAM Global Investors's AnaptysBio position peaked at $2.19M in Q4 2017.
131 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2022.

Based on EAM Global Investors's 13F filing for Q1 2022, filed 13 May 2022.